Today, Gubra announces an upgrade to its full-year 2024 financial outlook. Organic revenue growth for the CRO business is now expected to be 23-28% (previously 15-20%) and adjusted EBIT-margin is expected to be 29-32% (previously 28-31%). For the Discovery & Partnerships business, the 2024 outlook is unchanged.
The upgrade to the CRO business follows high activity in the first half of 2024 and solid current trading and orderbook. The main growth driver is the Obesity area where Gubra is a leading provider of high-end preclinical Obesity services.
Outlook for 2024
| Key ratio | New outlook for 2024 | Previous outlook for 2024* |
| CRO Segment | ||
| Organic revenue growth y/y | 23-28% | 15-20% |
| Adjusted EBIT-margin | 29-32% | 28-31% |
| Discovery & Partnerships Segment | ||
| Number of new partnerships per year | 1-2 | 1-2 |
| Total costs (adjusted) | DKK 160-170m | DKK 160-170m |
| Total costs excl. Amylin asset (adjusted) | DKK 115-125m | DKK 115-125m |
* Previous outlook announced 6 May 2024.
First half results 2024 will be published in Gubra’s half-year report 2024 on 22 August 2024.
